Translational Study of Alzheimer's Disease (AD) biomarkers from brain tissues in AβPP/PS1 mice and serum of AD patients

Journal of Alzheimer's Disease

Volumn 45, Issue 1, 2015, Pages 269-282

  Sun, Yingni ^a   Rong, Xianfang ^a   Lu, Wenwen ^a   Peng, Ying ^a   Li, Jiang ^a   Xu, Shaofeng ^a   Wang, Ling ^a   Wang, Xiaoliang ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Alzheimer's disease; biomarker; diagnosis; neurodegeneration; proteomics; serum; transgenic mice

Indexed keywords

BIOLOGICAL MARKER; CATHEPSIN B; CENTAURIN BETA 1; COFILIN 2; DYNAMIN I; ENOLASE; ENOLASE 2; PROGRAMMED CELL DEATH 6 INTERACTING PROTEIN; PROTEIN; UNCLASSIFIED DRUG; VOLTAGE DEPENDENT ANION CHANNEL 1; AMYLOID PRECURSOR PROTEIN; PRESENILIN 1; PSEN1 PROTEIN, HUMAN;

ALTERNATIVE RNA SPLICING; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN TISSUE; CONTROLLED STUDY; DOWN REGULATION; HIPPOCAMPUS; HUMAN; IMMUNOBLOTTING; LIQUID CHROMATOGRAPHY; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SILVER STAINING; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION; WESTERN BLOTTING; WILD TYPE; AGED; ANIMAL; BLOOD; BRAIN; DISEASE MODEL; FEMALE; GENETICS; MALE; MENTAL HEALTH; MUTATION; PATHOLOGY; REGRESSION ANALYSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BIOMARKERS; BRAIN; DISEASE MODELS, ANIMAL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; MALE; MENTAL STATUS SCHEDULE; MICE; MUTATION; PRESENILIN-1; REGRESSION ANALYSIS; TANDEM MASS SPECTROMETRY;

EID: 84924200328     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-142805     Document Type: Article

References (67)

1. Maarouf CL, Andacht TM, Kokjohn TA, Castano EM, Sue LI, Beach TG, Roher AE (2009) Proteomic analysis of Alzheimer's disease cerebrospinal fluid from neuropathologically diagnosed subjects. Curr Alzheimer Res 6, 399-406.
2. Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers HL, Hooper C, Rijsdijk F, Tabrizi SJ, Banner S, Shaw CE, Foy C, Poppe M, Archer N, Hamilton G, Powell J, Brown RG, Sham P, Ward M, Lovestone S (2006) Proteome-based plasma biomarkers for Alzheimer's disease. Brain 129, 3042-3050.
3. Lehmann S, Delaby C, Touchon J, Hirtz C, Gabelle A (2013) Biomarkers of Alzheimer's disease: The present and the future. Rev Neurol (Paris) 169, 719-723.
4. Kiddle SJ, Sattlecker M, Proitsi P, Simmons A, Westman E, Bazenet C, Nelson SK, Williams S, Hodges A, Johnston C, Soininen H, Kloszewska I, Mecocci P, Tsolaki M, Vellas B, Newhouse S, Lovestone S, Dobson RJ (2014) Candidate blood proteome markers of Alzheimer's disease onset and progression: A systematic review and replication study. J Alzheimers Dis 38, 515-531.
5. Galasko D (2005) Biomarkers for Alzheimer's disease-clinical needs and application. J Alzheimers Dis 8, 339-346.
6. Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, D'Angelo G, Malone JP, Townsend RR, Morris JC, Fagan AM, HoltzmanDM (2010) YKL-40: A novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry 68, 903-912.
7. Kandimalla RJ, Anand R, Veeramanikandan R, Wani WY, Prabhakar S, Grover VK, Bharadwaj N, Jain K, Gill KD (2014) CSF ubiquitin as a specific biomarker in Alzheimer's disease. Curr Alzheimer Res 11, 340-348.
8. Liguori C, Stefani A, Sancesario G, Sancesario GM, Marciani MG, Pierantozzi M (2014) CSF lactate levels, tau proteins, cognitive decline: A dynamic relationship in Alzheimer's disease. J Neurol Neurosurg Psychiatry, doi: 10.1136/jnnp-2014-308577.
9. Schmidt C, Gerlach N, Peter C, Gherib K, Lange K, Fride T, Zerr I (2015) Cerebrospinal fluid apolipoprotein E concentration and progression of Alzheimer's disease. J Alzheimers Dis, doi: 10.3233/JAD-141581.
10. Yang MH, Yang YH, Lu CY, Jong SB, Chen LJ, Lin YF, Wu SJ, Chu PY, Chung TW, Tyan YC (2012) Activity-dependent neuroprotector homeobox protein:Acandidate protein identified in serum as diagnostic biomarker for Alzheimer's disease. J Proteomics 75, 3617-3629.
11. Sun Q, Hampel H, Blennow K, Lista S, Levey A, Tang B, Li R, Shen Y (2014) Increased plasma TACE activity in subjects with mild cognitive impairment and patients with Alzheimer's disease. J Alzheimers Dis 41, 877-886.
12. Leung R, Proitsi P, Simmons A, Lunnon K, Guntert A, Kronenberg D, Pritchard M, Tsolaki M, Mecocci P, Kloszewska I, Vellas B, Soininen H, Wahlund LO, Lovestone S (2013) Inflammatory proteins in plasma are associated with severity of Alzheimer's disease. PLoS One 8, e64971.
13. Zabel M, Schrag M, Mueller C, ZhouW, Crofton A, Petersen F, Dickson A, KirschWM (2012) Assessing candidate serum biomarkers for Alzheimer's disease: A longitudinal study. J Alzheimers Dis 30, 311-321.
14. Kiko T, Nakagawa K, Tsuduki T, Furukawa K, Arai H, Miyazawa T (2014) MicroRNAs in plasma and cerebrospinal fluid as potential markers for Alzheimer's disease. J Alzheimers Dis 39, 253-259.
15. Galimberti D, Villa C, Fenoglio C, Serpente M, Ghezzi L, Cioffi SM, Arighi A, Fumagalli G, Scarpini E (2014) Circulating miRNAs as potential biomarkers in Alzheimer's disease. J Alzheimers Dis 42, 1261-1267.
16. Zhang J, Zhang CH, Li RJ, Lin XL, Chen YD, Gao HQ, Shi SL (2014) Accuracy of urinary AD7c-NTP for diagnosing Alzheimer's disease: A systematic review and meta-analysis. J Alzheimers Dis 40, 153-159.
17. Webster SJ, Bachstetter AD, Nelson PT, Schmitt FA, Van Eldik LJ (2014) Using mice to model Alzheimer's dementia: An overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. Front Genet 5, 88.
18. Vercauteren FG, Clerens S, Roy L, Hamel N, Arckens L, Vandesande F, Alhonen L, Janne J, Szyf M, Cuello AC (2004) Early dysregulation of hippocampal proteins in transgenic rats with Alzheimer's disease-linked mutations in amyloid precursor protein and presenilin 1. Brain Res Mol Brain Res 132, 241-259.
19. Sultana R, Robinson RA, Di Domenico F, Abdul HM, St Clair DK, Markesbery WR, Cai J, Pierce WM, ButterfieldDA (2011) Proteomic identification of specifically carbonylated brain proteins in APP (NLh)/APP (NLh) x PS-1 (P264L)/PS-1 (P264L) human double mutant knock-in mice model of Alzheimer disease as a function of age. J Proteomics 74, 2430-2440.
20. Rifai N, Gillette MA, Carr SA (2006) Protein biomarker discovery and validation: The long and uncertain path to clinical utility. Nat Biotechnol 24, 971-983.
21. Jankowsky JL, Slunt HH, Ratovitski T, JenkinsNA, Copeland NG, Borchelt DR (2001) Co-expression of multiple transgenes in mouse CNS: A comparison of strategies. Biomol Eng 17, 157-165.
22. Lu W, Wan X, Liu B, Rong X, Zhu L, Li P, Li J, Wang L, Cui L, Wang X (2014) Specific changes of serum proteins in Parkinson's disease patients. PLoS One 9, e95684.
23. Peng Y, Hu Y, Xu S, Li P, Li J, Lu L, Yang H, Feng N, Wang L, Wang X (2012) L-3-n-butylphthalide reduces tau phosphorylation and improves cognitive deficits in AβPP/PS1-Alzheimer's transgenic mice. J Alzheimers Dis 29, 379-391.
24. Cao H, Garcia F, McNiven MA (1998) Differential distribution of dynamin isoforms in mammalian cells. Mol Biol Cell 9, 2595-2609.
25. Sultana R, Boyd-Kimball D, Cai J, Pierce WM, Klein JB, Merchant M, Butterfield DA (2007) Proteomics analysis of the Alzheimer's disease hippocampal proteome. J Alzheimers Dis 11, 153-164.
26. Martin B, Brenneman R, Becker KG, Gucek M, Cole RN, Maudsley S (2008) iTRAQ analysis of complex proteome alterations in 3xTgAD Alzheimer's mice: Understanding the interface between physiology and disease. PLoS One 3, e2750.
27. Singh VK, Yang YY, Singh EA (1992) Immunoblot detection of antibodies to myelin basic protein in Alzheimer's disease patients. Neurosci Lett 147, 25-28.
28. Selkoe DJ, Brown BA, Salazar FJ, Marotta CA (1981) Myelin basic protein in Alzheimer disease neuronal fractions and mammalian neurofilament preparations. Ann Neurol 10, 429-436.
29. Rhein V, Song X, Wiesner A, Ittner LM, Baysang G, Meier F, Ozmen L, Bluethmann H, Drose S, Brandt U, Savaskan E, Czech C, Gotz J, Eckert A (2009) Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci U S A 106, 20057-20062.
30. Sundelof J, Sundstrom J, Hansson O, Eriksdotter-Jonhagen M, Giedraitis V, Larsson A, Degerman-Gunnarsson M, Ingelsson M, Minthon L, Blennow K, Kilander L, Basun H, Lannfelt L (2010) Higher cathepsin B levels in plasma in Alzheimer's disease compared to healthy controls. J Alzheimers Dis 22, 1223-1230.
31. Kindy MS, Yu J, Zhu H, El-Amouri SS, Hook V, Hook GR (2012) Deletion of the cathepsin B gene improves memory deficits in a transgenic ALZHeimer's disease mouse model expressing AβPP containing the wild-type β-secretase site sequence. J Alzheimers Dis 29, 827-840.
32. Hook V, Hook G, Kindy M (2010) Pharmacogenetic features of cathepsin B inhibitors that improve memory deficit and reduce β-amyloid related to Alzheimer's disease. Biol Chem 391, 861-872.
33. Zhou JW, Cheng XR, Cheng JP, Zhou WX, Zhang YX (2012) The activity and mRNA expression of β-secretase, cathepsin D, and cathepsin B in the brain of senescence-accelerated mouse. J Alzheimers Dis 28, 471-480.
34. Owen JB, Di Domenico F, Sultana R, Perluigi M, Cini C, Pierce WM, Butterfield DA (2009) Proteomics-determined differences in the concanavalin-A-fractionated proteome of hippocampus and inferior parietal lobule in subjects with Alzheimer's disease and mild cognitive impairment: Implications for progression of AD. J Proteome Res 8, 471-482.
35. Palumbo B, Siepi D, Sabalich I, Tranfaglia C, Parnetti L (2008) Cerebrospinal fluid neuron-specific enolase: A further marker of Alzheimer's disease? Funct Neurol 23, 93-96.
36. Ross GW, O'Callaghan JP, Sharp DS, Petrovitch H, Miller DB, Abbott RD, Nelson J, Launer LJ, Foley DJ, Burchfiel CM, Hardman J, White LR (2003) Quantification of regional glial fibrillary acidic protein levels in Alzheimer's disease. Acta Neurol Scand 107, 318-323.
37. Sizova D, Charbaut E, Delalande F, Poirier F, High AA, Parker F, Van Dorsselaer A, Duchesne M, Diu-Hercend A (2007) Proteomic analysis of brain tissue from an Alzheimer's disease mouse model by two-dimensional difference gel electrophoresis. Neurobiol Aging 28, 357-370.
38. Shin SJ, Lee SE, Boo JH, Kim M, Yoon YD, Kim SI, Mook-Jung I (2004) Profiling proteins related to amyloid deposited brain of Tg2576 mice. Proteomics 4, 3359-3368.
39. Cao Y, Xiao Y, Ravid R, Guan ZZ (2010) Changed clathrin regulatory proteins in the brains of Alzheimer's disease patients and animal models. J Alzheimers Dis 22, 329-342.
40. Ciavardelli D, Silvestri E, Del Viscovo A, Bomba M, De Gregorio D, Moreno M, Di Ilio C, Goglia F, Canzoniero LM, Sensi SL (2010) Alterations of brain and cerebellar proteomes linked to Aβ and tau pathology in a female triple-transgenic murine model of Alzheimer's disease. Cell Death Dis 1, e90.
41. Tsuji T, Shiozaki A, Kohno R, Yoshizato K, Shimohama S (2002) Proteomic profiling and neurodegeneration in Alzheimer's disease. Neurochem Res 27, 1245-1253.
42. Yoo BC, Fountoulakis M, Cairns N, Lubec G (2001) Changes of voltage-dependent anion-selective channel proteins VDAC1 and VDAC2 brain levels in patients with Alzheimer's disease andDownsyndrome. Electrophoresis 22, 172-179.
43. Cuadrado-Tejedor M, Vilarino M, Cabodevilla F, Del Rio J, Frechilla D, Perez-Mediavilla A (2011) Enhanced expression of the voltage-dependent anion channel 1 (VDAC1) in Alzheimer's disease transgenic mice: An insight into the pathogenic effects of amyloid-&brta;. J Alzheimers Dis 23, 195-206.
44. Chou JL, Shenoy DV, Thomas N, Choudhary PK, Laferla FM, Goodman SR, Breen GA (2011) Early dysregulation of the mitochondrial proteome in a mouse model of Alzheimer's disease. J Proteomics 74, 466-479.
45. Manczak M, Reddy PH (2012) Abnormal interaction of VDAC1 with amyloid aβ and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease. Hum Mol Genet 21, 5131-5146.
46. Hafner A, Glavan G, Obermajer N, Zivin M, Schliebs R, Kos J (2013) Neuroprotective role of β-enolase in microglia in a mouse model of Alzheimer's disease is regulated by cathepsin X. Aging Cell 12, 604-614.
47. ReddyPH (2013) Is the mitochondrial outermembrane protein VDAC1 therapeutic target for Alzheimer's disease? Biochim Biophys Acta 1832, 67-75.
48. Manczak M, Sheiko T, Craigen WJ, Reddy PH (2013) Reduced VDAC1 protects against Alzheimer's disease, mitochondria, and synaptic deficiencies. J Alzheimers Dis 37, 679-690.
49. Zhang J, Goodlett DR, Quinn JF, Peskind E, Kaye JA, Zhou Y, Pan C, Yi E, Eng J, Wang Q, Aebersold RH, Montine TJ (2005) Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J Alzheimers Dis 7, 125-133; discussion 173-180.
50. Guerreiro N, Staufenbiel M, Gomez-Mancilla B (2008) Proteomic 2-D DIGE profiling of APP23 transgenic mice brain from pre-plaque and plaque phenotypes. J Alzheimers Dis 13, 17-30.
51. Korolainen MA, Auriola S, Nyman TA, Alafuzoff I, Pirttila T (2005) Proteomic analysis of glial fibrillary acidic protein in Alzheimer's disease and aging brain. Neurobiol Dis 20, 858-870.
52. Manavalan A, Mishra M, Feng L, Sze SK, Akatsu H, Heese K (2013) Brain site-specific proteome changes in aging-related dementia. Exp Mol Med 45, e39.
53. Zhou J, Jones DR, Duong DM, Levey AI, Lah JJ, Peng J (2013) Proteomic analysis of postsynaptic density in Alzheimer's disease. Clin Chim Acta 420, 62-68.
54. Schonberger SJ, Edgar PF, Kydd R, Faull RL, Cooper GJ (2001) Proteomic analysis of the brain in Alzheimer's disease: Molecular phenotype of a complex disease process. Proteomics 1, 1519-1528.
55. Skorobogatko YV, Deuso J, Adolf-Bryfogle J, Nowak MG, Gong Y, Lippa CF, Vosseller K (2011) Human Alzheimer's disease synaptic O-GlcNAc site mapping and iTRAQ expression proteomics with ion trap mass spectrometry. Amino Acids 40, 765-779.
56. Yao PJ, Zhu M, Pyun EI, Brooks AI, Therianos S, Meyers VE, Coleman PD (2003) Defects in expression of genes related to synaptic vesicle trafficking in frontal cortex of Alzheimer's disease. Neurobiol Dis 12, 97-109.
57. Takano M, Maekura K, Otani M, Sano K, Nakamura-Hirota T, Tokuyama S, Min KS, Tomiyama T, Mori H, Matsuyama S (2012) Proteomic analysis of the brain tissues from a transgenic mouse model of amyloid beta oligomers. Neurochem Int 61, 347-355.
58. Zhu L, Yu J, Shi Q, Lu W, Liu B, Xu S, Wang L, Han J, Wang X (2011) Strain- and age-related alteration of proteins in the brain of SAMP8 and SAMR1 mice. J Alzheimers Dis 23, 641-654.
59. David DC, Ittner LM, Gehrig P, Nergenau D, Shepherd C, Halliday G, Gotz J (2006) β-amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes. Proteomics 6, 6566-6577.
60. Korolainen MA, Nyman TA, Aittokallio T, Pirttila T (2010) An update on clinical proteomics in Alzheimer's research. J Neurochem 112, 1386-1414.
61. Mahul-Mellier AL, Strappazzon F, Petiot A, Chatellard-Causse C, Torch S, Blot B, Freeman K, Kuhn L, Garin J, Verna JM, Fraboulet S, Sadoul R (2008) Alix and ALG-2 are involved in tumor necrosis factor receptor 1-induced cell death. J Biol Chem 283, 34954-34965.
62. Strappazzon F, Torch S, Chatellard-Causse C, Petiot A, Thibert C, Blot B, Verna JM, Sadoul R (2010) Alix is involved in caspase 9 activation during calcium-induced apoptosis. Biochem Biophys Res Commun 397, 64-69.
63. Park SH, Lee JH, Lee GB, Byun HJ, Kim BR, Park CY, Kim HB, Rho SB (2012) PDCD6 additively cooperates with anti-cancer drugs through activation of NF-?B pathways. Cell Signal 24, 726-733.
64. Yamamoto-Furusho JK, Barnich N, Xavier R, Hisamatsu T, Podolsky DK (2006) Centaurin beta1 down-regulates nucleotide-binding oligomerization domains 1- and 2-dependent NF-?B activation. J Biol Chem 281, 36060-36070.
65. Minamide LS, Striegl AM, Boyle JA, Meberg PJ, Bamburg JR (2000) Neurodegenerative stimuli induce persistent ADF/cofilin-actin rods that disrupt distal neurite function. Nat Cell Biol 2, 628-636.
66. Minamide LS, Maiti S, Boyle JA, Davis RC, Coppinger JA, Bao Y, Huang TY, Yates J, Bokoch GM, Bamburg JR (2010) Isolation and characterization of cytoplasmic cofilin-actin rods. J Biol Chem 285, 5450-5460.
67. Pontrello CG, Sun MY, Lin A, Fiacco TA, DeFea KA, Ethell IM (2012) Cofilin under control of beta-arrestin-2 in NMDAdependent dendritic spine plasticity, long-term depression (LTD), and learning. Proc Natl Acad Sci U S A 109, E442-E451.